Yesterday, April 15, 2016, 33 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $87.49 to $774,759.30.

Highlighted Stocks Traded by Insiders:

York Water (YORW) - FREE Research Report

Newcomer Robert P, who is Director at York Water, bought 29 shares at $28.09 on April 15, 2016. Following this transaction, the Director owned 4,991 shares meaning that the stake was boosted by 0.58% with the 29-share transaction.

Gang Michael W, who is Director at York Water, bought 56 shares at $28.09 on April 15, 2016. Following this transaction, the Director owned 10,735 shares meaning that the stake was boosted by 0.53% with the 56-share transaction.

Waters Ernest J, who is Director at York Water, bought 3 shares at $28.09 on April 15, 2016. Following this transaction, the Director owned 538 shares meaning that the stake was boosted by 0.58% with the 3-share transaction.

Rasmussen Steven R, who is Director at York Water, bought 25 shares at $29.75 on April 15, 2016. Following this transaction, the Director owned 834 shares meaning that the stake was boosted by 3.03% with the 25-share transaction.

Keller Jody L, who is Director at York Water, bought 5 shares at $28.09 on April 15, 2016. Following this transaction, the Director owned 855 shares meaning that the stake was boosted by 0.58% with the 5-share transaction.

The shares most recently traded at $29.77, up $1.68, or 5.63% since the insider transaction. Historical insider transactions for York Water go as follows:

  • 4-Week # shares bought: 20
  • 4-Week # shares sold: 2,087
  • 12-Week # shares bought: 42
  • 12-Week # shares sold: 2,087
  • 24-Week # shares bought: 1,473
  • 24-Week # shares sold: 2,087

The average volume for York Water has been 43,500 shares per day over the past 30 days. York Water has a market cap of $383.1 million and is part of the utilities sector and utilities industry. Shares are up 19.77% year-to-date as of the close of trading on Wednesday.

The York Water Company impounds, purifies, and distributes drinking water. It owns and operates two wastewater collection and treatment systems; and has two reservoirs comprising Lake Williams and Lake Redman, which together hold up to approximately 2.2 billion gallons of water. The stock currently has a dividend yield of 2.08%. The company has a P/E ratio of 30.8. Currently, there are no analysts who rate York Water a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on YORW - FREE

TheStreet Quant Ratings

rates York Water as a

buy

. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, expanding profit margins, good cash flow from operations and solid stock price performance. We feel its strengths outweigh the fact that the company is trading at a premium valuation based on our review of its current price compared to such things as earnings and book value. Get the full

York Water Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Verint Systems (VRNT) - FREE Research Report

Fante Peter, who is Chief Legal Officer & CCO at Verint Systems, sold 9,413 shares at $35.74 on April 15, 2016. Following this transaction, the Chief Legal Officer & CCO owned 21,176 shares meaning that the stake was reduced by 30.77% with the 9,413-share transaction.

The shares most recently traded at $34.09, down $1.65, or 4.84% since the insider transaction. Historical insider transactions for Verint Systems go as follows:

  • 4-Week # shares sold: 16,468
  • 12-Week # shares sold: 16,468
  • 24-Week # shares sold: 18,900

The average volume for Verint Systems has been 686,000 shares per day over the past 30 days. Verint Systems has a market cap of $2.0 billion and is part of the technology sector and computer software & services industry. Shares are down 16.1% year-to-date as of the close of trading on Wednesday.

Verint Systems Inc. provides actionable intelligence solutions and value-added services worldwide. The company has a P/E ratio of 117.1. Currently, there are 6 analysts who rate Verint Systems a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on VRNT - FREE

TheStreet Quant Ratings

rates Verint Systems as a

hold

. The company's strengths can be seen in multiple areas, such as its increase in net income, expanding profit margins and growth in earnings per share. However, as a counter to these strengths, we also find weaknesses including a generally disappointing performance in the stock itself, disappointing return on equity and weak operating cash flow. Get the full

Verint Systems Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Jazz Pharmaceuticals (JAZZ) - FREE Research Report

Wilson Karen J, who is SVP, Finance & PAO at Jazz Pharmaceuticals, sold 5,007 shares at $150.00 on April 15, 2016. Following this transaction, the SVP, Finance & PAO owned 18,663 shares meaning that the stake was reduced by 21.15% with the 5,007-share transaction.

The shares most recently traded at $140.07, down $9.93, or 7.09% since the insider transaction. Historical insider transactions for Jazz Pharmaceuticals go as follows:

  • 4-Week # shares sold: 6,161
  • 12-Week # shares sold: 39,683
  • 24-Week # shares sold: 78,696

The average volume for Jazz Pharmaceuticals has been 668,000 shares per day over the past 30 days. Jazz Pharmaceuticals has a market cap of $8.2 billion and is part of the health care sector and drugs industry. Shares are down 4.85% year-to-date as of the close of trading on Wednesday.

Jazz Pharmaceuticals Public Limited Company, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. The company has a P/E ratio of 25.6. Currently, there are 10 analysts who rate Jazz Pharmaceuticals a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on JAZZ - FREE

TheStreet Quant Ratings

rates Jazz Pharmaceuticals as a

buy

. The company's strengths can be seen in multiple areas, such as its revenue growth, increase in net income, reasonable valuation levels, expanding profit margins and growth in earnings per share. We feel its strengths outweigh the fact that the company shows weak operating cash flow. Get the full

Jazz Pharmaceuticals Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.